Dimethoxytolyl propylresorcinol induces apoptosis and mitophagy in human leukemia cells through the PI3K/AKT pathway

Dimethoxytolyl propylresorcinol (UP302), a natural compound extracted from owing to its tyrosinase inhibitory and strong antioxidant properties, is used in whitening cosmetics. However, the role of UP302 has not been reported in cancer treatment. This study aimed to assess the antitumor activity of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer 2024, Vol.15 (1), p.103-112
Main Authors: Wei, Jianming, Zhong, Xiaojuan, Peng, Huiting, Cui, Bingqing, Yue, Xianlin, Sun, Zewei, Shi, Jing
Format: Article
Language:English
Subjects:
Antibodies
Apoptosis
Autophagy
Cancer
Cell cycle
Cell death
Cell growth
Cytotoxicity
Drug dosages
Kinases
Leukemia
Mitochondria
Oxidation
Proteins
Research Paper
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dimethoxytolyl propylresorcinol (UP302), a natural compound extracted from owing to its tyrosinase inhibitory and strong antioxidant properties, is used in whitening cosmetics. However, the role of UP302 has not been reported in cancer treatment. This study aimed to assess the antitumor activity of UP302 in different tumor cells. It inhibited the growth of certain cancer cell lines and especially in leukemia cells. Therefore, we investigated the antitumor effect of UP302 in leukemia by examining the cell cycle, apoptosis, reactive oxygen species levels (ROS) production, and changes in mitochondrial membrane potential. Our results demonstrated that UP302 inhibited the growth of leukemia cells both and and exerted a proapoptotic effect on MV411 and K562 cells, confirmed by flow cytometry and western blot analysis. Furthermore, UP302 promoted autophagy in MV411 and K562 cells. Transmission electron microscopy and western blot analysis showed that UP302 induced mitophagy in MV411 and K562 cells. In addition, the autophagy inhibitor chloroquine could enhance UP302-induced apoptosis, suggesting that UP302-mediated autophagy may be protective in MV411 and K562 cells. In conclusion, our study is the first to provide evidence for the anti-leukemia properties of UP302 and the potential clinical use of UP302 combined with autophagy inhibitors as a chemotherapeutic strategy for human leukemia.
ISSN:1837-9664
1837-9664
DOI:10.7150/jca.89243